Case‐control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes
Authors:
- Iii Woodie M. ZachryIZIii Woodie M. Zachry
- Quynhchau D. DoanQDQuynhchau D. Doan
- Jerry D. ClewellJCJerry D. Clewell
- Brien J. SmithBSBrien J. Smith
Abstract
Summary: Purpose: Although antiepileptic drugs (AEDs) with multisource generic alternatives are becoming more prevalent, no case‐control studies have been published examining multisource medication use and epilepsy‐related outcomes. This study evaluated the association between inpatient/emergency epilepsy care and the occurrence of a recent switch in AED formulation.Methods: A case‐control analysis was conducted utilizing the Ingenix LabRx Database. Eligible patients were 12–64 years of age, received ≥145 days of AEDs in the preindex period, had continuous eligibility for 6 months preindex, and no prior inpatient/emergency care. Cases received care between 7/1/2006 and 12/31/2006 in an ambulance, emergency room, or inpatient hospital with a primary epilepsy diagnosis. Controls had a primary epilepsy diagnosis in a physician's office during the same period. The index date was the earliest occurrence of care in each respective setting. Cases and controls were matched 1:3 by epilepsy diagnosis and age. Odds of a switch between “A‐rated” AEDs within 6 months prior to index were calculated.Results: Cases (n = 416) had 81% greater odds of having had an A‐rated AED formulation switch [odds ratio (OR) = 1.81; 95% confidence interval (CI) = 1.25 to 2.63] relative to controls (n = 1248). There were no significant differences between groups regarding demographics or diagnosis. Significant differences were found with regard to medical coverage type (case Medicaid = 4.6%, control Medicaid = 1.8%, p = 0.002). Post hoc analysis results excluding Medicaid recipients remained significant and concordant with the original analysis.Discussion: This analysis found an association between patients receiving epilepsy care in an emergency or inpatient setting and the recent occurrence of AED formulation switching involving A‐rated generics.Keywords
This publication has 22 references indexed in Scilit:
- The Economic Consequences of Generic Substitution for Antiepileptic Drugs in a Public Payer Setting: The Case of LamotrigineDisease Management, 2007
- Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug ClassesEpilepsia, 2007
- LETTERS/COMMENTARYEpilepsia, 2007
- The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsyClinical Therapeutics, 2007
- Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic DrugsEpilepsia, 2006
- Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsyBrain, 2006
- Mortality of Epilepsy in Developed Countries: A ReviewEpilepsia, 2005
- Outbreak of Anticonvulsant Intoxication in an Australian CityBMJ, 1970